Begin main content

Search

We found 6761 result(s)

2020 CADTH Symposium

Event Date: April 18, 2020 - April 21, 2020
Result type: Events

Join us in Toronto for the 2020 CADTH Symposium. Connect with Canadian and international experts in the objective assessment and evaluation of health technologies for three days of education, information sharing, and networking. Mark your calendar: 2020 CADTH Symposium
April 18 to 21, 2020
Sheraton Centre Toronto
Toronto, On...

Non-Pharmacological Interventions for Chronic Non-Cancer Pain: Acupuncture

Event Date: March 16, 2020
Result type: Events

Because of the prevalence and burden of chronic pain, and the associated opioid crisis in our country, health professionals are looking for non-pharmacological treatment options to recommend to their patients. Join CADTH for a webinar on the current evidence on acupuncture for chronic non-cancer pain. The target audience for this presentation is...

CADTH Lecture — Cost-Effectiveness of Naloxone Kits in Canadian High Schools and Community Centre Settings

Event Date: March 5, 2020
Result type: Events

Lecture Description The opioid crisis continues to devastate families and communities across Canada. According to the Public Health Agency of Canada, an estimated 12,800 Canadians died from an apparent opioid-related overdose between January 2016 and March 2019. This is a complex issue that requires a compassionate, multi-faceted, evidence-base...

dupilumab (Dupixent)

Last Updated: February 13, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: dupilumab
Indications: atopic dermatitis

  • Brand Name: Dupixent
  • Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
  • Project Number: SR0636-000
  • Project Status: Active
  • Submission Type: New

ixekizumab (Taltz )

Last Updated: February 25, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: ixekizumab
Indications: Ankylosing spondylitis

  • Brand Name: Taltz
  • Manufacturer: Eli Lilly Canada Inc.
  • Project Number: SR0630-000
  • Project Status: Active
  • Submission Type: New Indication

esketamine hydrochloride (TBC )

Last Updated: February 27, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: esketamine hydrochloride
Indications: Major depressive disorder (MDD), adults

  • Brand Name: TBC
  • Manufacturer: Janssen Inc.
  • Project Number: SR0621-000
  • Project Status: Active
  • Submission Type: New

ustekinumab (Stelara/Stelara I.V)

Last Updated: February 20, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: ustekinumab
Indications: Ulcerative colitis

  • Brand Name: Stelara/Stelara I.V
  • Manufacturer: Janssen Inc.
  • Project Number: SR0627-000
  • Project Status: Active
  • Submission Type: New Indication

Iron (III) Isomaltoside 1000 (Monoferric)

Last Updated: February 26, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: Iron (III) Isomaltoside 1000
Indications: iron deficiency anemia

  • Brand Name: Monoferric
  • Manufacturer: Pharmacosmos A/S
  • Project Number: SR0622-000
  • Project Status: Active
  • Submission Type: New

icosapent ethyl (Vascepa)

Last Updated: February 27, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: icosapent ethyl
Indications: Ischemic events in statin-treated patients

  • Brand Name: Vascepa
  • Manufacturer: HLS Therapeutics
  • Project Number: SR0619-000
  • Project Status: Active
  • Submission Type: New

vortioxetine hydrobromide (Trintellix )

Last Updated: February 24, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: vortioxetine hydrobromide
Indications: Major depressive disorder (MDD), adults.

  • Brand Name: Trintellix
  • Manufacturer: Lundbeck Canada Inc.
  • Project Number: SR0611-000
  • Project Status: Active
  • Submission Type: New